Category: Technology Licenses
Created On: 2022-04-28
Record Count: 20
- Drug Discovery
- cell therapy
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 336288
DART platform enables us to design multi-specific molecules that seek to exploit different mechanisms.
IPSCIO Record ID: 307594
The companies will partner to develop Licensorâ€™s next-generation bispecific antibody programs, epcoritamab (DuoBodyÂ®-CD3xCD20), DuoHexaBodyÂ®-CD37 and DuoBody-CD3x5T4. The collaboration combines Licensorâ€™s world-class discovery and development engine and next-generation bispecific antibody therapeutic candidates with Licenseeâ€™s deep clinical expertise, innovative antibody-drug conjugate (ADC) platform and global commercial leadership in hematological cancers. Licensorâ€™s DuoBody-CD3 technology engages and directs cytotoxic T cells selectively to tumors to elicit an immune response towards malignant tumor cells. Licenseeâ€™s ADC technology allows the delivery of a therapeutic toxin directly to cancer cells while sparing normal, healthy cells, providing for a more targeted, less toxic treatment approach.
Licensor is a biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Licensors technology base consists of validated and proprietary next generation antibody technologies – the DuoBodyÂ® platform for generation of bispecific antibodies, the HexaBodyÂ® platform, which creates effector function enhanced antibodies, the HexElectÂ® platform, which combines two co-dependently acting HexaBody molecules to introduce selectivity while maximizing therapeutic potency and the DuoHexaBodyÂ® platform, which enhances the potential potency of bispecific antibodies through hexamerization.
Licensee has a clinical expertise, innovative antibody-drug conjugate (ADC) platform and global commercial leadership in hematological cancers.
IPSCIO Record ID: 256278
Licensor grants to Licensee of Germany an exclusive, worldwide, license under the Licensor Licensed Technology to Exploit Licensed Products.
Licensor grants a worldwide, non-exclusive, perpetual, irrevocable and non-terminable license under the Collaboration Patents, as defined in the Collaboration Agreement, with the right to grant and authorize the grant of sublicenses, to Exploit Licensed Products.
GM-CSF Target means the whole or part of the human granulocyte macrophage-colony stimulating factor identified by the SWISS-PROT entry name CSF2 HUMAN and accession number P0414 l.
Antibodies are proteins produced by the body's immune system in response to the presence of antigens, such as bacteria, viruses or other disease causing agents. Antibodies of identical molecular structure that bind to a specific target are called monoclonal antibodies. Single-chain antibodies are genetically engineered antibodies that incorporate only the antigen binding domains of an antibody. Thus, SCAs have the binding specificity and affinity of monoclonal antibodies; however, in their native form they are only one-fifth to one-sixth the size of a monoclonal. The small size of SCAs typically gives them shorter half-lives than monoclonal antibodies, making them better suited for use in acute indications or in other indications where the large size of a monoclonal antibody would inhibit the compound from reaching the area of potential therapeutic activity. In addition, SCAs are a well-established discovery format-of-choice in generating antibodies from phage or yeast display libraries.
The field of use for this agreement otherwise is limited to not include the right to exploit the Products for Radioimmunoguided Surgery(TM), Reagents and kits in the research market for production and cloning of genes encoding Single Chain Antibodies and their fusions in a filamentous bacteriophage-derived vector system, and for expression and screening of Single Chain Antibodies fused with the minor coat protein or attachment or adsorption protein of filamentous bacteriophage, and, Single Chain Antibodies fused with, or for the assay or purification of, Tumor Necrosis l Factor alpha (TNF-a.) or Lymphotoxin.
Products for Radioimmunoguided SurgeryTM (RIGS'), in which a radiolabelled Single Chain Antibody is administered to a cancer patient; time elapses for preferential concentration of the radiolabelled Single Chain Antibody in neoplastic tissue and decrease of background radioactivity in the patient; and such preferentially concentrated radiolabelled Single Chain Antibody is detected within a surgical operative field by a detector probe placed in juxtaposition with tissue suspected of containing said radiolabelled Single Chain Antibody.
IPSCIO Record ID: 372435
Licensor grants a non-exclusive license to use the Licensor Trademarks in connection with the Development and Commercialization of the Products.
Compound means xx-011, its derivatives and variants, including molecules that bind both Product Targets and are specifically claimed in Patents that specifically claim the amino acid sequence of xx-011; and any other DART derived from the DART Platform that binds both Product Targets.
DART means a dual affinity re-targeting molecule consisting of two binding arms, whereby the first arm binds a specificity conferred by an antibody variable region and the second arm binds a specificity conferred by a different antibody variable region.
DART Platform means Licensors proprietary platform for generating DARTs.
Indication means a discrete clinically recognized form of a disease, including DLBCL, chronic lymphocytic leukemia, acute lymphoblastic leukemia, mantle cell lymphoma, and follicular lymphoma.
Licensor Trademarks means the trademark DART, trademarks which incorporate the acronym DART, and related logos.
xx-011 is a humanized CD19 x CD3 bispecific DART protein.
Product means any pharmaceutical product, including all forms, presentations, strengths, doses and formulations, including any method of delivery, containing a Compound alone or in combination with other active pharmaceutical ingredients, other than any active pharmaceutical ingredient that is owned or controlled by Licensor, including any Combination Product.
The patents include
— Covalent Diabodies And Uses Thereof;
— Covalent Diabodies And Uses;
— Deimmunized Serum-Binding Domains And Their Use For Extending Serum Half-Life;
— CD3-Binding Molecules Capable of Binding to Human and Non-Human CD3; and,
— Bi-Specific Diabodies That Are Capable Of Binding CD19 And CD3 And Uses Thereof.
B-cell malignancies include non-Hodgkin lymphomas (NHL) and chronic lymphocytic leukemia (CLL). These include Burkitt lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma. Prognosis and treatment depend on type and stage of the cancer.
The Field means all uses, including the diagnosis, treatment or prevention of any disease in humans. This agreement specifically discusses the development of xx-011 for Multiple 8-Cell Malignancies.
IPSCIO Record ID: 257238
BiTE Molecule means a polypeptide comprising a bi-specific Single Chain Antibody binding to T-cells.
Target means a cell-surface antigen. The list of proprietary targets is epha2, alpha – V, and, beta-3.
BiTE molecules are designed to direct the bodyâ€™s cytotoxic, or cell-destroying, T cells against tumor cells, and represent a new therapeutic approach to cancer therapy.
Licensee's product candidates aim to efficiently redirect the patientâ€™s immune response to tumor cells either through the use of specific recombinant antibodies for the eradication of cancer cells, as is the case with adecatumumab, or through BiTE molecules, which target cancer cells for elimination by the patientâ€™s own T cells.
IPSCIO Record ID: 344582
The patents are titled
(a) U.S. Patent Application Number 60/092,672, filed July 13, 1998, entitled â€œCancer Treatment Using Antibodies to Aminophospholipidsâ€ (UT SOUTHWESTERN File Reference UTSD0549PZ1);
(b) U.S. Patent Application Number 60/110,608, filed December 2, 1998, entitled â€œCancer Treatment Using Antibodies to Aminophospholipidsâ€ (UT SOUTHWESTERN File Reference UTSD0549PZ2);
(c) U.S. Patent Application Number 09/351,543, filed July 12, 1999, entitled â€œ Cancer Treatment Methods Using Antibodies to Aminophospholipidsâ€ (UT SOUTHWESTERN File Reference UTSD0549);
(d) U.S. Patent Application Number 09/351,862, filed July 12, 1999, entitled â€œ Cancer Treatment Kits Using Antibodies to Aminophospholipidsâ€ (UT SOUTHWESTERN File Reference UTSD0549-1);
Bavituximab is a monoclonal antibody that targets and binds to phosphatidylserine (â€œPSâ€), a highly immunosuppressive molecule that is usually located inside the membrane of healthy cells, but then â€œflipsâ€ and becomes exposed on the outside of cells in the tumor microenvironment, causing the tumor to evade immune detection. Bavituximab targets and binds to PS to block this immunosuppressive pathway and simultaneously activates adaptive immunity, thereby enabling the immune system to recognize and fight the tumor.
IPSCIO Record ID: 256279
Licensor grants a worldwide, co-exclusive, with Licensor, right and license, with the right to grant sublicenses, under the Licensor Collaboration Technology to make, have made, use, offer for sale, sell, and import any product that is not a BiTE Product for any use in humans.
BiTE Molecule means a polypeptide comprising a bi-specific Single Chain Antibody binding to T-cells.
Target means a cell-surface antigen. The list of proprietary targets is epha2, alpha – V, and, beta-3.
BiTE(R) molecules are part of a novel class of antibody derivatives that may have the potential to selectively direct and activate the human immune system to act against cancer cells. This action is believed to occur as a result of the molecule's stimulation of T cells to target and destroy cancer cells that express a specific antigen.
BiTE molecule targeting CD19 is for the potential treatment of certain lymphomas.
IPSCIO Record ID: 255299
MGD013 is a first-in-class bispecific DART molecule designed to provide coordinate blockade of two immune checkpoint molecules expressed on T cells, PD-1 and LAG-3, for the potential treatment of a range of solid tumors and hematological malignancies.
IPSCIO Record ID: 369249
Licensor grants an exclusive, worldwide, license, with the right to sublicense, under the HuMAb Technology and the Licensor Technology to research, develop, make, have made, use, sell, offer for sale and import
— Licensed Royalty-Bearing Products solely in the Antibody Targeting Technology Field, and,
— Anti-Mannose Products.
For Hybridoma Cell Lines; Research License, Licensor grants an exclusive, worldwide license, with the right to sublicense, under the HuMAb Technology to research, make, have made, transfer physical possession of, but not to sell, lease, offer to sell or lease, or otherwise transfer title to, the Hybridoma Cell Lines.
Licensor grants a non-exclusive, worldwide, license, with the right to sublicense, under the Research Patent to conduct research.
For Research Antibodies License, Licensor grants an exclusive, worldwide license, without the right to sublicense, under the HuMAb Technology and the Licensor Technology to use the Research Antibodies for the sole purpose of determining the antigen with respect to which each Research Antibody was raised.
Licensor, who has incorporated Licensee for business opportunities outside of Licensors core business, irrevocably, perpetually and forever assigns and conveys Licensors entire right, title and interest in and to each of the following Assigned Assets
— Antibody Targeting Patents;
— Antibody Targeting Know-How;
— Anti-Mannose Receptor HuMAb Antibodies;
— the Investigational New Drug Application # 11,508 and related governmental filings, and the right to make any future or foreign related filing on –X-1307;
— all quantities of Biological Materials, including those in the possession or control of counterparties to Assigned Contracts;
— all clinical inventories of –X-1307 in the possession or control of Licensor as of the Effective Date; and
— the agreements that are Assigned Contracts.
Anti-Mannose Product shall mean any pharmaceutical composition or formulation incorporating an Anti-Mannose Receptor HuMAb Antibody.
HuMAb MouseÂ® shall mean any of Licensors immunizable transgenic mice containing unrearranged human immunoglobulin heavy and light chain transgenes, each inserted into mouse chromosomes, but excluding the Additional Mice. HuMAb MiceÂ® shall mean more than one HuMAb Mouse.
The patents relate to Anti-FcyRI (CD64) antibodies.
— an antibody or fragment chemically attached or genetically fused to an antigen (including an antigen that is an antibody, or fragment thereof, that encodes an idiotype antigen), whereby the antibody, or fragment thereof, serves as a targeting means for delivering such antigen to an Antigen-Presenting Cell for the purpose of eliciting an immune response,
— an antibody or fragment chemically attached or genetically fused to a toxin or radionuclide, whereby the antibody, or fragment thereof, serves as a targeting means for delivering such toxin or radionuclide to an Antigen-Presenting Cell for the purpose of decreasing, down-regulating or eliminating the activity of such Antigen-Presenting Cell,
— an antibody or fragment chemically attached or genetically fused to a cytokine, adjuvant, or other immuno-modulatory compound, whereby the antibody, or fragment thereof, serves as a targeting means for delivering such compound to an Antigen-Presenting Cell for the purpose of modulating the activity of such Antigen-Presenting Cell, and
— an antibody, or fragment thereof, alone, whereby the antibody or fragment binds to a particular antigen on the surface of an Antigen-Presenting Cell and through such binding modulates the activity of such Antigen-Presenting Cell.
IPSCIO Record ID: 329718
(A) an exclusive, royalty-bearing right and license, with the right to grant sublicenses as set forth in this Agreement, under the Licensor Technology, the Licensor Collaboration Technology and the Joint Collaboration Technology, in each case solely to (1) sell, offer to sell, import, use, and otherwise Commercialize Non-Co-Promoted Products (other than MDX-1379) for any purpose in the Field in the United States; and
(2) sell, offer to sell, import, use and otherwise Commercialize Products for any purpose in the Field in the Royalty Territory; including, in each case ((1) and (2)), for use as monotherapy or for use together or in combination with Agents, other Immunotherapeutic Agents, or other vaccines, biologics or compounds; (3) sell, offer to sell, import, use and otherwise Commercialize MDX-1379 for all uses permitted by the PHS License for use in the Field in the Royalty Territory; and (4) make and have made Non-Co-Promoted Products (other than MDX-1379), Products and MDX 1379 for use in the activities set forth in this Agreement.
(B) a co-exclusive (with Licensor and its Affiliates), royalty-bearing right and license, with the right to grant sublicenses as set forth in this Agreement, under the Licensor Technology, the Licensor Collaboration Technology and the Joint Collaboration Technology, in each case solely to (1) sell, offer to sell, import, use and otherwise Commercialize Products (other than Non-Co-Promoted Products) for any purpose in the Field in the United States, including in each case for use as monotherapy or for use together or in combination with each Agent with respect to which the Co-Promotion Product is Developed in accordance with this Agreement; and (2) sell, offer to sell, import, use and otherwise Commercialize MDX-1379 for all uses permitted by the PHS License for use in the Field in the United States (but which license shall be exclusive if MDX-1379 is a Non-Co-Promoted Product); and
(3) make and have made Products and MDX-1379 (other than Non-Co-Promoted Products) for use in the activities set forth in this Agreement.
MDX-010 is a fully human antibody against human CTLA-4, a molecule on T cells that is believed to be responsible for suppressing the immune response. MDX-010 also has the potential to enable the immune systems of cancer patients to more effectively fight tumors.
Lead Antibody means MDX-010, which has the amino acid sequences for CDR 1, 2 and 3 of the heavy chain variable region as Previously Disclosed.
U.S. Patent No. 5,811,097 – Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
U.S. Patent No. 5,855,887 – Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
U.S. Patent No. 6,051,227 – Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
Antibody means any antibody, or fragment thereof, whether human, humanized, chimeric, murine or from any other source (and including bispecific antibodies, single chain antibodies, and immunoconjugated antibodies), that (a) has been raised, engineered or otherwise optimized to bind specifically and directly to the Target (whether exclusively or in addition to any other target such Antibody may modulate), and (b) once bound to the Target, has antagonistic activity against or otherwise blocks the immunosuppressive signaling of the Target. For clarification, (x) any antibody or fragment thereof, whether human, humanized, chimeric, murine or from any other source (and including bispecific antibodies, single chain antibodies, and immunoconjugated antibodies) that is Derived from an Antibody, binds specifically and directly to the Target, and otherwise meets the requirements of clause (b) above, shall be an Antibody for purposes of this Agreement and (y) any fusion protein comprised of a fragment of an Antibody and that uses such fragment in order to bind to the Target shall be considered an Antibody for purposes of this Agreement. For clarification, the Lead Antibody is an Antibody. For the avoidance of doubt, those fusion proteins known as CTLA4-Ig and LEA-29Y shall not be considered Antibodies for purposes of this Agreement.
Licensor Non-Collaboration Technology means (a) any and all Information, Materials and inventions (i) conceived, discovered, developed or otherwise made, solely by or on behalf of Licensor or its Affiliates or, to the extent permitted under the applicable sublicense agreement, its sublicensees (other than Licensee and its Affiliates), or (ii) acquired or otherwise used (but only to the extent Controlled) by Licensor or its Affiliates, in each case ((i) and (ii)), after the Execution Date and during the term of this Agreement, that are necessary or reasonably useful in the Development, Commercialization, manufacture or use of MDX-1379, an Antibody, Product or Non-Antibody Substance, whether or not patented or patentable, but excluding any (u) Excluded Technology, (v) Licensor Pre-Existing Technology, (w) Mice-Related Technology, (x) Mice Materials, (y) Collaboration Technology and (z) any Information, Materials and inventions conceived, discovered, developed or otherwise made, by or on behalf of Licensor, its Affiliates or sublicensees in connection with the clinical trials identified in this Agreement, unless and until such activities are set forth in a Global Development Plan and Budget and Licensee reimburses Licensor for Licenseeâ€™s share of such Development Costs as provided in this Agreement (collectively, â€œLicensor Non-Collaboration Know-Howâ€), and (b) Patents and other intellectual property rights with respect to the Information, Materials and inventions described in clause (a) above (collectively, â€œLicensor Non-Collaboration Patentsâ€); provided, however, upon termination of this Agreement pursuant to this Agreement with respect to a Product or MDX-1379, Licensor Non-Collaboration Technology shall be limited to (1) Licensor Non-Collaboration Know-How and Licensor Non-Collaboration Patents with respect to such Product or MDX-1379 that are in existence as of the date of termination, and (2) those Patents that are filed thereafter to the extent that they claim Licensor Non-Collaboration Know-How included in clause (1) above. For purposes of this definition, the determination of whether Information, Materials and inventions are conceived, discovered, developed or otherwise made by a Party for the purpose of allocating proprietary rights (including Patent, copyright or other intellectual property rights) therein, shall be made in accordance with Applicable Law in the United States.
Commercialize means to promote, market, distribute, sell (and offer for sale or contract to sell) or provide product support for a Product or MDX-1379.
Cancer means any type of cancer in any cell or organ in a human body, including any Core Cancer.
IPSCIO Record ID: 280819
For the Commercial License, Licensor grants an exclusive, worldwide license to make, have made, use, have used, sell, have sold, offer for sale, import and have imported Licensed Products for use in the Field directed to such Licensee Target under Licensor Background Inventions, and under Licensors rights in all Patent Rights and Collaboration Inventions and Collaboration Material pertaining to such Licensee Target and Licensed Products, or the uses thereof in the Field.
The two companies will collaborate on the development of human antibodies for the treatment of cancer.
IPSCIO Record ID: 184504
The original agreement entered into a broad, global alliance with the parties to discover, develop and commercialize novel immuno-therapeutics using the antibody platforms. The collaboration was initially focused on four CPM programs targeting GITR, OX40, TIM-3 and LAG-3, and in November 2015, was expanded by adding three novel undisclosed CPM targets.
GITR is an immune checkpoint agonist, one of a class of receptors that amplify the immune systemâ€™s response to cancer. GITR (glucocorticoid-induced TNFR-related protein) is a receptor expressed on select populations of T cells. Activation of GITR leads to a more powerful anti-tumor inflammatory response, increased production of inflammatory signaling molecules and increased resistance to immunosuppression.
OX40 (also known as CD134 and TNFRSF4), a member of the TNFR super-family, is an immune-response-enhancing receptor found on activated T cells. OX40 promotes proliferation of these activated T cells and prevents the immunosuppressive activity of inhibitory T cells. We believe that antibodies that activate OX40 may help increase immune system activity through both of these mechanisms. Furthermore, OX40 antibodies have the potential to work alone or in combination with other therapeutics. Combining with another agonist checkpoint antibody, which provides different, yet complementary signaling attributes may further augment anti-tumor responses.
IPSCIO Record ID: 289177
The Licensor of Scotland agrees to grant the German Licensee under the patent rights a non-exclusive world-wide licence to the extent necessary to commercialise the Deimmunised antibody and/or the deliverables in the field.
Licensor grants for each specific Deimmunised antibody a non-exclusive licence under the patent rights to the extent necessary for worldwide commercialisation of the Deimmunised antibody derived from the specific Single-Chain Antibody sequence.
Licensee is the owner of a cDNA which encodes a Single-Chain Antibody which binds to a specific antigen.
Licensor patent rights shall mean all patent applications and granted patents relevant to Deimmunization Technology.
Deimmunised antibody shall mean all genetically engineered variant(s) of the single-chain antibody arising from the research.
Deimmunization technology shall mean the technical process applied by Licensor to generate Deimmunised antibody as outlined in the research program.
DeImmunisation increases the clinical potential of antibody and protein therapeutics by eliminating/reducing the T-cell response caused when the therapeutic molecule is recognised as foreign by the patient's immune system. The technology is based on â€˜peptide threading' and works by identifying potential T-cell epitopes on the therapeutic antibody or protein. T-cell epitopes are sites on the therapeutic molecule which can bind to MHC class II, triggering a T-cell mediated immune response. Once this potentially immunogenic region of the antibody is identified, it is removed from the molecule by single amino acid substitutions, thus eliminating/reducing the therapeutic antibody or protein's immunogenicity and increasing its safety. This can be done without compromise to efficacy.
IPSCIO Record ID: 356291
For the Manufacturing Grant to Licensee, Licensor grants a co-exclusive license, including the right to sublicense through multiple tiers, under the Licensor Manufacturing Technology, Licensors interest in the Joint Technology, Licensor Patents and the Licensor Platform Technology, to Manufacture the Product for Development worldwide in the Field and for Commercialization in the Field in the Licensee Territory.
By this agreement, Licensor will have the exclusive commercialization rights in the United States and Canada and Licensee will have the exclusive commercialization rights in the rest of the world.
Compound xx414 means a bispecific polypeptide containing a Prostate Specific Membrane Antigen or PSMA Binding derived from murine antibody 107-1A4 and a CD3 Binding Domain derived from murine antibody CRIS-7 (xx414), and any back-up or follow-on compound comprised of a PSMA Binding Domain with or without other Binding Domains, including both a PSMA Binding Domain and a CD3 Binding Domain or both a PSMA Binding Domain and a Binding Domain other than CD3 Binding Domain; and any modification or derivative of the foregoing (including conjugated or mono/multi-specific forms thereof).
CD3 Antigen means the T cell receptor (TCR) complex or any one or more of the CD3 group of cell surface molecules found on T-cells, including TCRa, TCRb, CD3y, CD3d, and CD3e.
CD3 Binding Domain means a Binding Domain that binds the CD3 Antigen and which has greater binding selectivity for the CD3 Antigen versus other antigens (and, for purposes of this definition, disregarding any residual binding activity).
Product Inventions means all Inventions relating to a PSMA Binding Domain, including Inventions relating to composition of matter, method of use and method of manufacture of the Product.
PSMA Antigen means prostate specific membrane antigen (PSMA), also known as the enzyme glutamate carboxypeptidase II (GCPII), N-acetyl-L-aspartyl-L-glutamate peptidase I (NAALADase I), or NAAG peptidase.
The patents include
Prostate Specific Membrane Antigen Binding Proteins and Related Compositions and Methods,
CD3 Binding Polypeptides, Single Chain Multivalent Binding Proteins with Effector Function, Heterodimer Binding Proteins and Uses Thereof, and, Polypeptides Heterodimers and Uses Thereof.
Field means all fields of use, including therapeutic, palliative, prophylactic, diagnostic and research use, in human and animals.
Licensee has significant experience in the development of pharmaceutical products;
IPSCIO Record ID: 260370
The Regents grants to the Licensee a license under its rights in and to Property Rights to make, have made and use the Biological Materials to make, have made, use, Sell, offer for Sale and import Licensed Products, or to practice Licensed Methods, in the United States and in other countries where The Regents may lawfully grant such licenses, only in the Field of Use.
— High Affinity Human Antibodies to Novel Tumor Antigens;
— Bi-specific Single Chain Fv scFv Antibody Molecule; and,
— Human Erb-B Antibodies.
IPSCIO Record ID: 368653
Full Length Antigens shall mean the full length protein forms of the Licensor Antigens NY-ES0-1, NY-BR-1 and NY-C0-58.
Part Length Antigens shall mean Polypeptide Sequence forms of the Licensor Antigens MAGE-A3, Melan-A, and SSX2.
These antigens, previously identified and characterized immunologically by Licensor , will add to new Licensee development programs for a range of cancer types. NY-ESO-1, MAGE3, and MelanA, in particular, are being studied in non-small-cell-lung, ovarian, and bladder cancers, as well as melanoma in an extended series of Phase I/II programs conducted by the Licensor and its collaborators.
This agreements focus is cancer immunotherapy.
IPSCIO Record ID: 245920
Licensor grants an exclusive Option for each Research Antigen designated to obtain the Exclusive License set forth during the Option Period.
If Licensee elects to exercise its option to acquire an Exclusive License with respect to a particular Research Antigen, and Licensee pays the Option Exercise Fee, then subject to the terms and conditions of this Agreement, and commencing as of the date that Licensor has received the Option Exercise Fee from Licensee, Licensor is automatically deemed to grant, and in such event hereby grants, to Licensee, on a Research Antigen-by-Research Antigen basis, a worldwide, exclusive, even as to Licensor, nontransferable, royalty-bearing license under the Licensor Technology, with the right to sublicense, to discover, have discovered, to develop, have developed, make, have made, import, have imported, export, have exported, use, sell and have sold Products directed toward such Research Antigen within the Field in the Territory.
The licensors patents and technology are for Antibodies, Research Antigens, Exclusive Antigens, and Jointly-Invented Inventions Related thereto.
Antigen means any protein, including any glyco- or lipo-protein, carbohydrate, compound or other composition, and any fragment, peptide or epitope thereof, to which an antibody hinds.
Product means any and all products where the manufacture, sale or use of such products would have constituted a misappropriation of Drug Conjugation Technology, Licensor Know-How, Improvements or New Technologies, and/or an infringement of the Licensed Patents but for the licenses granted in this Agreement.
The binding of an antibody to the surface of a cancer cell rarely induces cell death by itself. Enhancing the potency of antibodies through the linkage of drug payloads provides a means to selectively kill cancer cells while limiting damage to normal tissue.
IPSCIO Record ID: 296181
The November amendment adds an additional dual-reactive antibody product candidate.
The AnaptysBio platform offers unmatched capabilities in antibody discovery, generation and optimization, and we are excited about the potential for these programs. We look forward to working with the AnaptysBio team to develop novel immuno-oncology-based approaches to a variety of tumors.
IPSCIO Record ID: 286413
AGEN1884 is a type of immunotherapy, a treatment that acts to improve the immune systemâ€™s ability to target and kill cancer cells.
IPSCIO Record ID: 291107
Collaborator Patent Right means any Patent Right that (a) is Controlled by Collaborator or any of its Affiliates as of the Effective Date (including the Collaborator Patent Rights that comes into the Control of Collaborator or any of its Affiliates during the Term (other than through the grant of a license by Licensee) and (b) claims or discloses any (i) Antibody or Product (including the composition of matter thereof), (ii) method of making any Antibody or Product or materials used in any method of making any Antibody or Product, or (iii) methods of using any Antibody or Product.
Collaborator Technology means the Collaborator Patent Rights and Collaborator Know-How.
Patent Rights means any and all (a) issued patents, (b) pending patent applications, including all provisional applications, substitutions, continuations, continuations-in-part, divisions and renewals, and all patents granted thereon, (c) patents-of-addition, reissues, reexaminations and extensions or restorations by existing or future extension or restoration mechanisms, including patent term adjustments, patent term extensions, supplementary protection certificates or the equivalent thereof, (d) inventorâ€™s certificates, (e) other forms of government-issued rights substantially similar to any of the foregoing and (f) United States and foreign counterparts of any of the foregoing.
1. The Identification and Selection of individual Human B cell donors
Pre-requisites to I-STAR screen
â€¢ Initiate blood (B cell) collection program for non-small cell lung carcinoma.
â€¢ 200 donors to be screened serologically prior to selection for I-STAR memory B cell activation.
â€¢ Perform serum binding assay against NSCLC tumor cell lines.
â€¢ Selection of top 50 subjects/ B cell donors with serum reactivity against NSCLC tumor cell lines for IgG+ memory B cell isolation and activation (I-STAR platform). Subject selection to be done by Pfizer/ Theraclone joint project team.
2. I-STAR process for selection of native human bNAbs
I-STAR Antibody Discovery Platform
â€¢ Perform activation of short-term memory B cell cultures (B cell expansion and differentiation) from a total of 50 selected individuals.
â€¢ 2000-20,000 native human memory B cell clones from each of 50 selected donors to be activated in vitro in preparation for screening assay.
â€¢ Perform a two step screening process to identify NSCLC binding antibodies.
o Primary screening by a high-throughput cell binding assay with NSCLC tumor cell lines using supernatant from cultured B cells. Primary screens will provide initial identification of antibody binding of up to 10 tumor cell lines. The NSCLC tumor cell lines will be chosen by the Pfizer/ Theraclone joint project team. Screening will utilize pools of three to four tumor cell lines to increase throughput.
o Perform secondary screens on tumor cell line binding antibodies. Secondary screens will assess binding to NSCLC tumor cell lines by suitable techniques, and lack of binding to a normal cell line. Normal cells lines will be chosen by the joint project team.
â€¢ Deep sequencing of up to 2,880 hit wells to be performed and sequence analysis allowing clustering of hits into bins (based on V-region (VH / VL sequences). All DNA and amino acid sequences delivered to Pfizer.
â€¢ Joint project team to prioritize up to 200 mAbs for small scale expression.
3. Generation of recombinant mAh protein and re-screening against target cells
â€¢ Generation (expression and purification) of transiently transfected full-length, human mAbs from mammalian cells in an appropriate human IgG format for up to 200 target antigen positive V-region hits.
â€¢ Initial characterization of recombinant mAbs to confirm NSCLC tumor cell line binding, internalization and binding to disaggregated cells from PDX tissue.
â€¢ Develop an internalization assay based on cell killing by auristatin conjugates. Several antibodies, including anti-EGFR, anti-HER2, anti-transferrin receptor and TCN-462 will be evaluated as potential internalization control antibodies.
4. Generation of large scale recombinant mAh protein, characterization data and re-screening against targets
â€¢ Selection of up to 50 unique antibodies that the joint project team regards suitable for further analysis
â€¢ Selection criteria
o Binding to NSCLC PDX tissue
o Binding to cancer cells in vitro, Ko determination by tumor cell binding
o Lack of binding to normal cell lines
o Internalization into NSCLC tumor cell lines
â€¢ mAb expression and purification at Theraclone – highest 50 prioritized mAbs at 5 – 20 mg scale. Additional prioritized mAbs purified at 5-20 mg scale subject to joint project team approval.
â€¢ Quality control A280, SDS-PAGE, CIEX, SEC, target I antigen binding profile, endotoxin analysis